Clinical Trials Logo

Acute Gout clinical trials

View clinical trials related to Acute Gout.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05983445 Recruiting - Acute Gout Clinical Trials

Safety & Efficacy of Genakumab in Patients With Frequent Flares

Start date: January 15, 2023
Phase: Phase 3
Study type: Interventional

To evaluate the safety and tolerability of single subcutaneous injection of Genakumab for Injection in patients with acute gout

NCT ID: NCT05936268 Recruiting - Gout Flare Clinical Trials

Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare

Gensci 048-203
Start date: June 30, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of Genakumab for Injection in patients with gout flare as a first line therapy

NCT ID: NCT05698680 Recruiting - Acute Gout Clinical Trials

Prednisolone Versus Colchicine for Acute Gout in Primary Care

COPAGO
Start date: January 18, 2023
Phase: Phase 4
Study type: Interventional

Gout is the most common form of rheumatic disease in which monosodium urate crystals are deposited in the joints followed by acute inflammatory reactions. There are various approved drugs that can be prescribed for pain relief during an acute gout attack. However to date, no direct comparison of efficacy of colchicine and prednisolone for the treatment of acute gout attacks has been investigated. Furthermore, majority of previous research studies were not only conducted in tertiary centres but also excluded patients with common comorbidities due to contraindications with naproxen. This pragmatic, prospective, double-blind, parallel-group, randomized, non-inferiority trial will investigate whether prednisolone (treatment drug) is comparable or only acceptably worse than treatment with colchicine (comparison drug) in patients presenting with acute gout. Patients presenting with acute gout to their general practitioners in 60 practices across 3 university sites (Greifswald, Göttingen, and Würzburg) will be invited to participate. Patients often excluded by previous studies due to contraindications with naproxen will also be able to participate. The investigators will compare the absolute levels of the most severe pain on day 3 (in the last 24 hours) measured with an 11-item numerical rating scale as the primary endpoint. Day 0 is the day patients take their study medication for the first time. They are then asked to fill out a study diary at the same time each day to quantify their pain. Pain scores will then be used as comparison between the two medications.

NCT ID: NCT05588908 Recruiting - Acute Gout Clinical Trials

A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Start date: June 29, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the target dose of phase II and to evaluate the safety, tolerability, pharmacokinetics and efficacy of recombinant anti-IL-1β humanized monoclonal antibody injection at different doses in Chinese participants with acute gout.